A promising FASN inhibitor, IPI‐9119, has shown potential in preclinical studies by significantly reducing cell growth, causing cell cycle arrest and triggering apoptosis in prostate cancer cells [77]. This evidence concerns the gene FASN and prostate carcinoma.